17 completed, 4 terminated, 1 active not recruiting. 9 Phase 1, 9 Phase 2, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 8, Terminated 1 |
| Phase 2 | 9 | Completed 5, Terminated 4 |
| Phase 3 | 5 | Completed 4, Active not recruiting 1 |
Follow pharmaand GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Rucaparib - Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer | Phase 3 | Completed | pharmaand GmbH | 34 | 2021-03-22 | 2024-05-07 |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes Rucaparib - Solid Tumor | Phase 2 | Terminated | pharmaand GmbH | 83 | 2020-01-16 | 2023-10-02 |
| Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) Rucaparib, Enzalutamide, Abiraterone - Metastatic Castration Resistant Prostate Cancer | Phase 1 | Completed | pharmaand GmbH | 8 | 2019-12-05 | 2023-06-29 |
| A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat Farydak - Multiple Myeloma | Completed | pharmaand GmbH | 248 | 2019-11-04 | 2023-06-15 | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) Rucaparib, Nivolumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Terminated | pharmaand GmbH | 1 | 2019-08-23 | 2023-06-12 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) Rucaparib, Lucitanib, Sacituzumab govitecan - Ovarian Cancer, Triple-negative Breast Cancer | Phase 1 / Phase 2 | Terminated | pharmaand GmbH | 25 | 2019-06-28 | 2024-01-16 |
| Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives Rucaparib, Rosuvastatin, Oral Contraceptives - Neoplasms | Phase 1 | Completed | pharmaand GmbH | 36 | 2019-04-25 | 2023-06-08 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Rucaparib - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | pharmaand GmbH | 97 | 2018-06-01 | 2023-06-09 |
| A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy Rucaparib, Nivolumab, Placebo Oral Tablet - Epithelial Ovarian Cancer, Primary Peritoneal | Phase 3 | Active not recruiting | pharmaand GmbH | 1097 | 2018-05-14 | 2025-06-24 |
| Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor Rucaparib camsylate - Neoplasms | Phase 1 | Completed | pharmaand GmbH | 16 | 2018-02-27 | 2023-06-09 |
| A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor Rucaparib - Advanced Solid Tumor | Phase 1 | Completed | pharmaand GmbH | 29 | 2018-02-06 | 2023-06-09 |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel - Metastatic Castration Resistant Prostate Cancer | Phase 3 | Completed | pharmaand GmbH | 405 | 2017-06-13 | 2025-07-25 |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Chemotherapy, Rucaparib - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 3 | Completed | pharmaand GmbH | 349 | 2017-03-01 | 2023-06-09 |
| A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Rucaparib - Metastatic Castration Resistant Prostate Cancer | Phase 2 | Completed | pharmaand GmbH | 277 | 2017-02-15 | 2023-06-09 |
| Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib C-14 labeled Rucaparib, Rucaparib - Solid Tumor | Phase 1 | Completed | pharmaand GmbH | 6 | 2016-11-01 | 2023-06-09 |
| Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets - Multiple Myeloma | Phase 2 | Completed | pharmaand GmbH | 248 | 2016-04-27 | 2024-07-12 |
| Pharmacokinetic Drug-Drug Interaction Study of Rucaparib Caffeine, Warfarin, Omeprazole - Neoplasms | Phase 1 | Completed | pharmaand GmbH | 17 | 2016-04-01 | 2023-06-09 |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) Rucaparib, Placebo - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | pharmaand GmbH | 564 | 2014-04-07 | 2023-06-09 |
| A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Rucaparib - Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma | Phase 2 | Completed | pharmaand GmbH | 19 | 2014-04-01 | 2023-06-13 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) Oral rucaparib - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 | Completed | pharmaand GmbH | 491 | 2013-10-30 | 2023-06-12 |
Showing 20 of 22. Sign in to see all of them.
Fallopian Tube Neoplasms (8) · Ovarian Neoplasms (7) · Carcinoma, Ovarian Epithelial (5) · Neoplasms (4) · Recurrence (4) · Carcinoma, Transitional Cell (2) · Multiple Myeloma (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Urinary Bladder Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Endometrioid (1) · Carcinosarcoma (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1)
rucaparib (20) · Abiraterone Acetate (2) · Carboplatin (2) · Nivolumab (2) · Panobinostat (2) · enzalutamide (2) · Bortezomib (1) · CP protocol (1) · Caffeine (1) · Calcium Dobesilate (1) · Cisplatin (1) · Contraceptives, Oral (1) · Dexamethasone (1) · Digoxin (1) · Docetaxel (1)
United States (15) · United Kingdom (11) · Canada (9) · Spain (9) · Israel (8) · Italy (8) · Poland (7) · Australia (6) · France (6) · Germany (6) · Belgium (5) · Hungary (4) · Russia (4) · Czechia (3) · Denmark (3)
Heidi Giordano (2) · Kathleen N Moore, MD (1) · Kim Reiss-Binder, MD (1)
PMID 35397664, PMID 31685558, PMID 32203306, PMID 35170751, PMID 36898948, PMID 27908594, PMID 28222073, PMID 28916367, PMID 29799676, PMID 30427584, PMID 32359490, PMID 32861537, PMID 33301738, PMID 33941784, PMID 34030643, PMID 34370076, PMID 34593565, PMID 35298906, PMID 35658487, PMID 36482193, PMID 36795891, PMID 37262961, PMID 37277275, PMID 39914419, PMID 40632975, PMID 41115469
2016 (3), 2015 (2), 2017 (2), 2018 (1)